Scinai Immunotherapeutics Ltd. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunomodulation therapies for infectious diseases. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The firm's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.
Scinai Immunotherapeutics Ltd の最大収益セグメントは Software as a Service (SaaS) and Platform as a Service (PaaS) で、最新の利益発表における収益は 1,008,448,000 です。地域別に見ると、United States が Scinai Immunotherapeutics Ltd の主要市場であり、収益は 1,014,168,000 です。